Core Viewpoint - The article highlights the evolution and modernization of Lisheng Pharmaceutical, emphasizing its commitment to public health and innovation while maintaining its historical roots through the "Three Fish" brand established in 1930 [1][2]. Group 1: Company History and Philosophy - Lisheng Pharmaceutical was founded in 1930 to address the lack of affordable medicine for the public, with the "Three Fish" trademark symbolizing its commitment to making medicine accessible [2]. - The company's philosophy of "for the people" has been a guiding principle, focusing on the integration of raw materials and formulations to ensure affordability and availability of medications [2]. Group 2: Innovation and Product Development - Lisheng has increased its R&D investment, with over 8% of its budget allocated to research in the first half of 2025, resulting in the approval of key products and multiple patent applications [3]. - The company is focusing on high-end generic drugs, modified new drugs for specific populations, and original innovations in critical areas such as synthetic biology and gene therapy [3]. Group 3: Brand Modernization and Marketing Strategy - The "Three Fish" brand has been revitalized to resonate with younger consumers, incorporating cultural narratives and modern marketing strategies such as short online dramas to enhance brand visibility [4][6]. - Lisheng has developed a multi-channel marketing network, utilizing OTC, medical, and online platforms to reach diverse consumer groups effectively [6][7]. - The "Shoubi Mountain" brand is transitioning from a single product to a comprehensive series of antihypertensive medications, with plans to expand its product range significantly [7].

Group 1 - The flu epidemic in China is at a high level, primarily driven by the H3N2 strain, with increased transmission risk due to upcoming population movements during the New Year holiday [1] - Demand for antiviral and symptomatic medications has surged, with a reported over 500% increase in flu-related drug purchases on Alibaba Health and over 100% increase in orders for traditional Chinese medicine on Meituan [1] - The pharmaceutical industry is responding effectively across the supply chain, from vaccine production to drug distribution, indicating a well-coordinated effort to manage the public health challenge [1][2] Group 2 - Vaccine companies are ramping up production, with Hualan Vaccine reporting 55 batches of flu vaccine issued since November, reflecting increased public willingness to get vaccinated [2] - Diagnostic companies like Dian Diagnostics and Kingmed Diagnostics are seeing increased business, supporting the trend of testing before treatment, which enhances rational drug use [2] - The treatment landscape is diversifying, with both chemical and traditional Chinese medicines being utilized, indicating a shift in market dynamics [3][5] Group 3 - Traditional Chinese medicine is gaining traction, with companies like China Resources Sanjiu and Kangyuan Pharmaceutical seeing strong growth in their antiviral product lines [5] - The distribution sector is crucial, with companies like Yiyigou ensuring rapid delivery of essential medications during peak demand periods [5] - The clinical relevance of traditional Chinese medicine is increasing, supported by government policies that endorse its use in flu treatment, leading to a rise in evidence-based research [6][9] Group 4 - Companies are focusing on clinical research to validate the efficacy of traditional Chinese medicines, with Kangyuan Pharmaceutical conducting head-to-head trials against conventional drugs [7][9] - The competitive landscape in the respiratory system traditional Chinese medicine market is diverse, with companies like China Resources Sanjiu and Yiling Pharmaceutical leveraging brand strength and market recognition [9] - As the industry moves towards evidence-based medicine, companies with strong research capabilities and clinical data are likely to capture more market opportunities [9]

今日具体限售解禁股情况如下： | 股票简称 | 股票代码 | 限售股类型 | 解禁股数 | | --- | --- | --- | --- | | 力生制药 | 002393 | 股权激励限售流通 | 49.7万 | | 雪峰科技 | 603227 | 增发A股法人配售上市 | 9761.72万 | | 苏盐井神 | 603299 | 股权激励限售流通 | 62.27万 | | 千禾味业 | 603027 | 股权激励限售流通 | 204.3万 | | 鸿铭股份 | 301105 | 发行前股份限售流通 | 337.5万 | | 富乐德 | 301297 | 发行前股份限售流通 | 2亿 | | 佰维存储 | 688525 | | 1.14亿 | 智通财经APP获悉，12月30日共有7家上市公司的限售股解禁，解禁总市值约115.51亿元。 ...

证券代码：002393 证券简称：力生制药 公告编号：2025-089 天津力生制药股份有限公司 重要提示： 1.本次解除2022年限制性股票激励计划首次授予部分第二次解除限售的股票数量为 583,044股，占公司总股本0.2263%，涉及股东人数66人； 2.本次解除限售的股份上市流通日期为：2025年12月30日。 天津力生制药股份有限公司（以下简称"公司"或"本公司"）于2025年12月05日召开第八 届董事会第二次会议审议通过了《关于2022年限制性股票激励计划首次授予部分第二个解 除限售期解除限售条件成就的议案》。公司董事会认为公司2022年限制性股票激励计划首 次授予部分的第二个解除限售期已符合解除限售条件。 根据公司2022年第五次临时股东大会审议授权及公司2022年限制性股票激励计划相关 规定，公司办理了2022年限制性股票激励计划首次授予部分第二次解除限售并上市流通手 续，现就有关事项说明如下： 一、公司股权激励计划简述及实施情况 关于 2022 年限制性股票激励计划首次授予部分 第二次解除限售并上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记载、 ...

（文章来源：证券日报） 证券日报网讯 12月24日，力生制药发布公告称，公司以闲置募集资金8500万元认购兴业银行天津分行 182天期保本浮动收益型结构性存款，预计年化收益1.20%-1.60%。截至公告日，尚未到期现金管理余额 1.55亿元，未超6亿元授权上限。 ...

天津发展(00882)发布公告，于2025年12月24日，力生制药（002393）(公司间接非全资附属公司)与兴业 银行订立第12份兴业银行理财协议，以本金金额人民币8500万元(相当于约港币9340.66万元)认购另一项 结构性存款。 ...

天津力生制药股份有限公司（以下简称"公司"）于2025年3月19日召开第七届董事会第 五十次会议、2025年4月11日召开2024年度股东大会，审议通过了《关于公司2025年使用 闲置募集资金进行现金管理额度的议案》，同意公司在不影响募集资金投资项目实施的情 况下，使用额度不超过人民币6亿元闲置募集资金购买安全性高、流动性好、由募集户银行 （招商银行、兴业银行或邮储银行）发行的短期理财产品，期限不超过股东大会批准之日 起12个月，在上述额度及期限范围内资金滚动使用。针对上述事项，公司保荐机构发表了 明确的同意意见。具体内容详见公司于2025年3月21日在巨潮资讯网(www.cninfo.com.cn） 披露的《关于公司2025年使用闲置募集资金进行现金管理额度的公告》（公告编号： 2025-025）及《渤海证券关于天津力生制药股份有限公司使用闲置募集资金购买理财产品 的核查意见》。 一、本次进行现金管理购买理财产品情况 公司以募集资金共计8,500万元人民币在兴业银行股份有限公司天津分行（以下简称"兴 业银行"）购买结构性存款。具体情况如下： | 产品名称： | 结构性存款 | | --- | --- | | ...

证券日报网讯12月23日，力生制药（002393）在互动平台回答投资者提问时表示，公司子公司中央药业 持有的是天士力（600535）生物医药产业集团有限公司12.15%股权。 ...

证券日报网讯12月23日，力生制药（002393）在互动平台回答投资者提问时表示，公司股东人数在定期 报告中进行披露，最新股东户数请关注公司已于2025年10月24日在深圳证券交易所发布的《2025年第三 季度报告》。 ...

（文章来源：证券日报） 证券日报网讯 12月22日晚间，力生制药发布公告称，公司2025年第四次临时股东会审议通过《关于聘 任公司2025年度审计机构的提案》等。 ...